Holland JF - Search Results

1

Androgens induce the expression of vascular endothelial growth factor in human fetal prostatic fibroblasts.

Levine AC, Liu XH, Greenberg PD, Eliashvili M, Schiff JD, Aaronson SA, Holland JF, Kirschenbaum A. Levine AC, et al. Among authors: holland jf. Endocrinology. 1998 Nov;139(11):4672-8. doi: 10.1210/endo.139.11.6303. Endocrinology. 1998. PMID: 9794479

2

Inhibition of vascular endothelial cell growth factor suppresses the in vivo growth of human prostate tumors.

Kirschenbaum A, Wang JP, Ren M, Schiff JD, Aaronson SA, Droller MJ, Ferrara N, Holland JF, Levine AC. Kirschenbaum A, et al. Among authors: holland jf. Urol Oncol. 1997 Jan-Feb;3(1):3-10. doi: 10.1016/s1078-1439(97)00001-x. Urol Oncol. 1997. PMID: 21227046

3

Upregulation of vascular endothelial growth factor by cobalt chloride-simulated hypoxia is mediated by persistent induction of cyclooxygenase-2 in a metastatic human prostate cancer cell line.

Liu XH, Kirschenbaum A, Yao S, Stearns ME, Holland JF, Claffey K, Levine AC. Liu XH, et al. Among authors: holland jf. Clin Exp Metastasis. 1999;17(8):687-94. doi: 10.1023/a:1006728119549. Clin Exp Metastasis. 1999. PMID: 10919714

4

Inhibition of cyclooxygenase-2 suppresses angiogenesis and the growth of prostate cancer in vivo.

Liu XH, Kirschenbaum A, Yao S, Lee R, Holland JF, Levine AC. Liu XH, et al. Among authors: holland jf. J Urol. 2000 Sep;164(3 Pt 1):820-5. doi: 10.1097/00005392-200009010-00056. J Urol. 2000. PMID: 10953162

5

Serum of patients with prostatic cancer or benign prostatic hypertrophy contains nonpolar testosterone.

Addo SB, Holland JF, Kirschenbaum A, Mandeli J, Hollander VP. Addo SB, et al. Among authors: holland jf. Steroids. 1990 Nov;55(11):491-4. doi: 10.1016/0039-128x(90)90086-q. Steroids. 1990. PMID: 1706116

6

Detection of mammary tumor virus env gene-like sequences in human breast cancer.

Wang Y, Holland JF, Bleiweiss IJ, Melana S, Liu X, Pelisson I, Cantarella A, Stellrecht K, Mani S, Pogo BG. Wang Y, et al. Among authors: holland jf. Cancer Res. 1995 Nov 15;55(22):5173-9. Cancer Res. 1995. PMID: 7585568

7

Clinical activity and safety of the dual pathway inhibitor rigosertib for higher risk myelodysplastic syndromes following DNA methyltransferase inhibitor therapy.

Silverman LR, Greenberg P, Raza A, Olnes MJ, Holland JF, Reddy P, Maniar M, Wilhelm F. Silverman LR, et al. Among authors: holland jf. Hematol Oncol. 2015 Jun;33(2):57-66. doi: 10.1002/hon.2137. Epub 2014 Apr 29. Hematol Oncol. 2015. PMID: 24777753 Free article.

8

Modulation of platelet-derived growth factor-beta mRNA expression and cell growth in a human mesothelioma cell line by a hammerhead ribozyme.

Dorai T, Kobayashi H, Holland JF, Ohnuma T. Dorai T, et al. Among authors: holland jf. Mol Pharmacol. 1994 Sep;46(3):437-44. Mol Pharmacol. 1994. PMID: 7935323

9

Fibroblast growth inhibitor.

Rogalsky V, Svet-Moldavsky I, Arlin Z, Den T, Holland JF. Rogalsky V, et al. Among authors: holland jf. Biomed Pharmacother. 1988;42(8):547-53. Biomed Pharmacother. 1988. PMID: 3224159

10

Inhibitory effects of telomere-mimic phosphorothioate oligonucleotides on various human tumor cells in vitro.

Ohnuma T, Li FL, Holland JF. Ohnuma T, et al. Among authors: holland jf. Anticancer Res. 1997 Jul-Aug;17(4A):2455-8. Anticancer Res. 1997. PMID: 9252662

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

620 results

Search Page

Filters